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INTRODUCTION
Congenital leukemia, defined as a leukemia that occurs
within 4 to 6 weeks of birth, is rare. Excluding Down syn-
drome-related transient neonatal myeloproliferation, its inci-
dence is less than 1% of all childhood leukemia (1, 2). The
diagnostic criteria include the presence of immature leukemic
blasts in the blood and in extrahematopoietic tissues and the
absence of congenital infections (syphilis, toxoplasmosis, her-
pes simplex, cytomegalovirus, rubella, and bacterial infec-
tions), hypoxia, and hemolytic disease, which may produce
a similar clinical and hematological picture. In addition, there
may be absence of chromosomal disorders that may be asso-
ciated with unstable hematopoiesis, such as trisomy 21 (3). 
Although its biology and natural history are still under
investigation, it is clear that the leukemic process originat-
ed in utero even in infants diagnosed within the first few
months of life (2). In infants with congenital leukemia under
the age of 1 month, the 6-month survival rate is only one third
despite aggressive chemotherapy (4). It has a higher mortal-
ity rate than any other congenital cancer, but recently some
reports showed spontaneous remissions (3, 5). These findings
implicate therapeutic dilemmas on deciding which patients
to treat or to wait. 
Here we present a case of congenital myeloid leukemia (M5)
initially characterized by the presence of leukemia cutis and
hyperleukocytosis with chromosomal abnormality (double
translocation of t[8;16][p11;p13.2] and t[17;19][?;q13.3]).
With the fear of toxic effect of chemotherapeutic agents, par-
ents did not agree to chemotherapy at first. Three weeks later
we started chemotherapy but the prognosis was poor. We
report our experience and review previous cases in view of
treatment dilemmas. 
CASE REPORT
A term male infant weighing 3,360 gram was born to a
32-yr-old woman after uncomplicated pregnancy. There was
no history of exposure to radiation, any known teratogens,
smoking, drinking, or drug use from his mother. A cesarean
section was done for previous section. Gross examination of
the infant noted at birth to have an unusual purpuric rash on
his whole body looking like ‘‘blueberry-muffin’’ rash (Fig. 1).
Physical examination showed no hepatosplenomegaly and
there were no dysmorphic features. Skin examination revealed
widespread, scattered, yellowish-colored firm nodules with
multiple purpuric macules and papules predominantly on
the face and proximal extremities with a few present on the
trunk. A punch-biopsy of a nodule showed proliferation of
atypical hematologic cells in the dermis. Blood count at birth
revealed white blood cell count of 173×109/L with 58.8%
neutrophils, 5.3% lymphocytes, 26.1% monocytes, and 0.5%
eosinophils; hemoglobin of 13.9 g/dL; platelets of 133×109/L.
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Congenital Acute Myeloid Leukemia with t(8;16) and t(17;19) Double
Translocation: Case Presentation and Literature Review
Congenital leukemia is uncommon and excluding transient myeloproliferation asso-
ciated with Down syndrome, makes up approximately 1% of childhood leukemias.
A newborn boy was born with multiple subcutaneous nodules and large purpuric
papules. Skin biopsy revealed proliferation of atypical hematologic cells in the der-
mis. Bone marrow morphology was consistent with acute myeloid leukemia (M5)
and cytogenetic studies revealed t(8;16) and t(17;19) double translocation. Although
prognosis of congenital leukemia is known to be dismal, recent reports showed spon-
taneous remissions. With the fear of chemotherapy-related toxicity, to treat or not
to treat may be a dilemma both to parents and pediatricians. We report our experi-
ence and review the literature.
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TORCH titers (against toxoplasmosis, cytomegalovirus, her-
pes simplex virus, rubella, and syphilis) were all negative and
blood cultures were also negative. Peripheral blood morphol-
ogy showed marked leukocytosis with 32% of immature cells
and monocytosis. Immunophenotyping showed that blasts
were positive for CD14, CD33 and HLA-DR(+). Flow cytom-
etry on the bone marrow showed the blasts to be acute mye-
loid leukemia (M5) in the French-American-British classifi-
cation based on the morphologic features and special stains.
Bone marrow aspiration and biopsy also showed 90% of leu-
kemic blasts. The results of special stain were peroxidase (+),
PAS (-), ANAE with NaF inhibition (+). Cytogenetic anal-
ysis revealed 46, XY karyotype with multiple chromosomal
defect, t(8;16)(p11;p13.2), t(17;19)(?;q13.3). Serial white
blood cell count showed a progressive rise up to 256×109/L
with thrombocytopenia of 88×109/L. Leukemia cutis also
progressed and it became more pronounced on the face and
somewhat hardened. Parents only wanted conservative treat-
ment at first. Three weeks after birth, parents agreed to che-
motherapy. Initial chemotherapy was started with daunoru-
bicin, etoposide, and cytarabine, but, he died at 27 days of age. 
DISCUSSION
Leukemia is the most common malignancy presented dur-
ing the childhood, however, congenital leukemia is a very rare
disease, representing less than 1% of all childhood leukemia.
It should be differentiated from transient leukemoid reaction
and other small round cell tumors (3). 
Several risk factors are known to be associated with the
development of congenital leukemia. Maternal alcohol con-
sumption, tobacco smoking, maternal exposures to radiation,
high birth weight, high levels of insulin-like growth factors,
maternal consumption of topoisomerase II inhibitors, such
as fruits and vegetables, coffee, tea, cocoa, wine, and soybeans
are those factors (2, 6). However, as in our case, some had been
reported to have no known risk factors. Frequently, reported
cases of congenital leukemia with constitutional chromoso-
mal abnormalities have led to suspicion whether congenital
leukemia is a result of chromosomal fragility (2). 
Congenital leukemia may reflect the early onset of intrauter-
ine leukemia, that is, leukemic process originated in utero
even in infants diagnosed within the first few months of life.
Since embryonic hematopoiesis begins in undifferentiated
mesenchyme starting the third week after fertilization, leu-
kemia cutis may be a primary event and the first manifesta-
tion of congenital leukemia (6). 
Prognosis of congenital leukemia is dismal and has a pro-
gressive downhill course, even with chemotherapy. However,
there are some reported cases of spontaneous remission (Table
1) (3, 7-19). The reason that spontaneous remissions may
occur in newborn infants is unclear (1). The period of spon-
taneous remission varied widely from months to years, and
several of the children with relapses remained in prolonged
remission after chemotherapy (3, 15). There appear to be no
common clinical features between those who progressed and
those that had spontaneous remissions. Neither bone marrow
involvement at diagnosis nor hyperleukocytosis appears to
increase the risk of relapse (3, 4, 15-17, 19). Chromosome
abnormalities affecting chromosome 11 band q23 are involv-
ed in the majority of infant leukemia cases. The major trans-
locations involving the 11q23 locus are t(4;11) and t(11;19)
(13, 16). Translocation involving 11q23 band or reciprocal
translocations involving chromosomes 8 and 16 are known
to be mapped with oncogene(s) and are known to be associ-
ated with a poor prognosis (6, 10, 30). Hence, even cytoge-
netic abnormality of 11q23 rearrangement of skin without
involvement of bone morrow was also treated aggressively (6).
Moreover, AML with the t(8;16) is associated with a young
age at diagnosis, myelomonocytic (FAB M4) or monocytic
(FAB M5) morphology, erythrophagocytosis, disseminated
intravascular coagulation and a poor outcome (9). 
The gene at 11q23, known as MLL (ALL-1, HRX, HTRX,
Fig. 1. Gross view of the skin. (A, B) There are widespread, scattered, yellowish-colored firm nodules with multiple purpuric macules and
papules predominantly on the face and the trunk. 
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*One case of Warrier had incomplete data and omitted it.  
ND, no data.
Case Reference
Bone 
marrow
infiltration
Sex
Age
at 
diagnosis
Leu-
kemia
cutis
FAB Karyotype
Chemotherapy
given
Age at 
relapse
Outcome
Leukocy-
tosis
(100 
>10
9/L)
With spontaneous remission
1 Landers (7) Male Birth Yes No 23% blasts M4 46,XY, t(5;9) No No Alive at 8 months
2 Van Den Berg (8) Female Birth Yes No Normal M2 46,XX No No Alive at 41 months
3 Weintraub (9) Male 1 week Yes No 70-80% blasts M4 46, XX, t(8;16) No No Alive at 15 months
(q11;p13)
4 Grundy (5) Male Birth Yes No Normal M4/M5 46,XX No No Alive at 26 months
5 Dinulos(3) Male Birth Yes No Normal M5 46,XY, inv(9) No No Alive at 4 yr
6 Female 1 week Yes No 30% blasts M4 46,XX, t(8;16) Yes at 24  Alive at 44 months
(p11;p13) del(9) relapse months
(q12;q32) at relapse
7 Male Birth Yes No ND M5 46,XY Yes at  16  Alive at 6 yr
relapse months
8 Sainati (10) Male Birth Yes No 62% blasts M5 46,XY, t(8;6) No No Alive at 18 months
(p11;p13)
9 Mayer (11) Female Birth Yes No 90%  M5 46,XX, t(5;6) No No Alive at 10 months
monoblasts (q31;q21)
10 Gottesfeld (12) Male Birth Yes No 25% blasts M5 ND No No Alive at 24 months
11 Issacs (13) Male Birth Yes Yes Involved AML 46,XY No No Alive at 6 yr 
12 Lampkin (14) Female  Birth Yes Yes 52% blasts M5 46,XX No No Alive at 16 yr
13 Chu (15)  Female Birth No Yes Involved AML 46,XX Yes at relapse 3 weeks Alive at 16 yr 
14 Lilleyman (16) Male Birth Yes No Involved M5 46,XY Yes at relapse 3 months Dead 
15 Penchansky (17) Male  6 weeks No No 20% blasts M1 46,XY Yes at relapse 12 yr Dead 
16 Monpoux (18)  Male  Birth Yes No Dry tap M5 46,XY, t(9;11) Yes at relapse 3 months Dead
(p21-22;q23) at relapse
17 Francis (19) Male  Birth Yes No Involved M5 46,XY Yes at relapse 12 months Alive at 10 yr
Without spontaneous remission
18 Zhang (6) Female Birth Yes No 11% blasts AML 11q23  Yes Dead at 3 days
rearrangement
19 Ferguson (4) Male  Birth No Yes ND M1 46,XY, t(6;17) Yes Dead at 2 days
(q23;q11.2)
20 Morerio (20)   Female Birth No No ND M5b 46,XX, t(10;11) Yes Dead at 45 days
(p11.2;q23)
21 Fernandez (21)  Male  Birth Yes Yes 30% blasts M5b 46,XY, t(5;11) Yes No Alive at 17 months
(q31;q23)
22 Mori (22) Male  Birth Yes No Involved M6/M7 46,XY Yes No Alive at 14 months
23 Carroll (23) Female 4 weeks ND No 30% blasts M7 46,XX, t(1;22) Yes Dead
(p13;q13)
24 Female  4 weeks ND No 7% blasts M7 46,XX, t(1;22) No Dead before 
(p13;q13) chemotheray
25 Hanada (24) Male  2 weeks Yes No 57% blasts M5b 46,XY, t(8;16) Yes ND
(p11;p13)
26 Ohyashiki (25) Male  Birth Yes Yes 90% blasts M5b 46, XY, t(11;19) No Dead before 
(q23;p13) chemotherapy
27 Sait (26) Male  Birth Yes No 30% blasts M7 46,XY, t(1;22) Yes Dead
(p13;q13.3)(p21;p23)
28 Resnik (27) Male  Birth Yes Yes 68% blasts M5 46,XY, t(6;17),  Yes Dead
t(13;11)
29 McCoy (28) Female  Birth Yes Yes ND M4 46,XX, t(8;22) No Dead before 
(p11;q13) chemotherapy
30 Warrier* (29) Female Birth No Yes ND AML 46,XX, 18p Yes Dead
31 Pui (30) Male  Birth No Yes 25% blasts M4 46,XY, t(10;11) Yes ND
(p11;q23)
32 this case Male Birth Yes Yes 90% blasts M5 t(8;16)(p11;p13.2),  Refuse/Yes Dead at 3 days 
t(17;19)(?;q13.3)
Table 1. Reported cases of congenital nonlymphocytic leukemia from 1980 to 2007948 T.-J. Sung, D.-H. Lee, S.-K. Kim, et al.
or Hu-ets-1), is required for the production of normal num-
bers of hematopoietic precursors and for their proper differ-
entiation (2, 13). Chromosomal translocations can theoreti-
cally occur between any gene loci. 11q23-MLL gene rearrange-
ments after DNA damage occur most frequently with AML.
Translocations involving MLL may fuse with other genes and
hence MLL usually retains at least two DNA binding domains
(2, 13). Since there are a few reports of double translocations
as our case, exact meaning of double gene translocation is yet
to be discussed. 
Because of the rarity of this disease, there is no standard pro-
tocol of chemotherapy. Treating congenital leukemia means
exposure of the toxic chemotherapeutic agents to the neonate.
Although there had been reported cases of prolonged periods
of remission, rapidly downhill course were also noted in some
cases and some of them died after relapse during the course of
chemotherapy (16-18). While some cases with t(8; 16) remit-
ted spontaneously without treatment (3, 9, 10), paradoxical-
ly, those who had chromosomal abnormalities died after ini-
tiation of chemotherapy as our case (4, 6, 20, 23, 26-29). It
seems like that karyotypic findings in blasts in the neonatal
period may not be predictive of whether or not a spontaneous
remission will occur (2).
For our case, hyperleukocytosis, progressive leukemia cutis,
bone marrow involvement, double translocation involving
(8;16) made us to decide to treat at first. However, with the
fear of unknown toxic effect of chemotherapeutic agents, par-
ents refused to treat. Three weeks later after parents’ agree-
ment, we treated with daunorubicin, etoposide, and cytara-
bine but he died of pulmonary hemorrhage three days after
induction chemotherapy. He may died of leukemia itself but,
we are not sure whether he died due to chemotherapy or he
could have survived with only conservative management as
other spontaneous remitted cases. That is because it is the first
case of congenital AML with double translocation of (8;16)
and (17;19) to be reported in the English literature to the
best of our knowledge. 
Although congenital leukemia remains a rare disorder, an
international collection of data or register system is indispens-
able for establishing an optimal treatment protocols. 
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